LUX-Lung 7: A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung

Trial Profile

LUX-Lung 7: A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Afatinib (Primary) ; Gefitinib
  • Indications Lung cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms LUX-Lung 7
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2017 Results of a retrospective analysis from LUX-Lung (LL) 3, 6 and 7 studies assessing subsequent therapy outcomes in patients with common EGFR mutations, who were randomised to 1st-line afatinib, presented at the 42nd European Society for Medical Oncology Congress.
    • 07 Jul 2017 Planned End Date changed from 1 Jun 2017 to 31 May 2018.
    • 11 Oct 2016 Results assessing Time to Treatment Failure (TTF) presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top